ArticleRespiratory medicine case reports2026
Pulmonary artery intimal sarcoma masquerading as pulmonary embolism during therapeutic apixaban: A case report.
Article in Respiratory medicine case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary artery intimal sarcoma (PAIS) is a rare intravascular malignancy that can closely resemble pulmonary embolism (PE). A 65-year-old man receiving therapeutic apixaban for atrial fibrillation presented with 3 weeks of progressive exertional dyspnea. Computed tomography pulmonary angiography showed a large unilateral filling defect in the left main pulmonary artery with occlusion of the left upper- and lower-lobe branches, initially interpreted as PE. However, the D-dimer was low, bilateral lower-extremity ultrasonography showed no deep venous thrombosis, cardiac biomarkers were normal, and echocardiography showed preserved right ventricular size and function without pulmonary hypertension. Contrast-enhanced chest magnetic resonance imaging demonstrated an enhancing lobulated, frond-like proximal pulmonary artery mass with mild arterial expansion and a separate distal nonenhancing component consistent with bland thrombus. Pulmonary thromboendarterectomy with tumor debulking confirmed high-grade PAIS. The patient subsequently received doxorubicin, ifosfamide, and mesna with pembrolizumab followed by proton radiotherapy. This case emphasizes that a unilateral central pulmonary artery filling defect should prompt tumor-directed imaging when the thromboembolic burden is discordant with biomarkers, venous imaging, and right-heart physiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.